Jack A. Khattar insider trades

Open-market stock purchases and sales by Jack A. Khattar, President, CEO at Supernus Pharmaceuticals, Inc, from SEC Form 4 filings since May 4, 2012.

Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +52%.

Recent trades

DateStockTradeValue
Aug 12, 2026SUPN Supernus Pharmaceuticals, IncSold (not open market)$589K
Aug 12, 2026SUPN Supernus Pharmaceuticals, IncBought (not open market)—
Jul 29, 2026SUPN Supernus Pharmaceuticals, IncBought (not open market)—
Jun 17, 2026CGTX Cognition Therapeutics IncBought (not open market)—
Mar 13, 2026SUPN Supernus Pharmaceuticals, IncSold (not open market)—
Mar 13, 2026SUPN Supernus Pharmaceuticals, IncSold$1.2M
Mar 13, 2026SUPN Supernus Pharmaceuticals, IncSold$548K
Mar 13, 2026SUPN Supernus Pharmaceuticals, IncSold$6.2K
Mar 6, 2026SUPN Supernus Pharmaceuticals, IncSold (not open market)$907K
Mar 6, 2026SUPN Supernus Pharmaceuticals, IncBought (not open market)—
Feb 28, 2026SUPN Supernus Pharmaceuticals, IncBought (not open market)—
Feb 18, 2026SUPN Supernus Pharmaceuticals, IncBought (not open market)—

Companies traded

  • SUPN Supernus Pharmaceuticals, Inc: 3 buys, 41 sales, last Aug 12, 2026
  • CGTX Cognition Therapeutics Inc: other filings, last Jun 17, 2026
  • SCPH scPharmaceuticals Inc: 1 buy, last Oct 7, 2025

Get free alerts when Jack A. Khattar files a new trade →